Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0P8BE
|
||||
| Former ID |
DNC012055
|
||||
| Drug Name |
(3-Methyl-indol-1-yl)-propyl-pyridin-4-yl-amine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [534087] | ||
| Formula |
C17H19N3
|
||||
| Canonical SMILES |
CCCN(C1=CC=NC=C1)N2C=C(C3=CC=CC=C32)C
|
||||
| InChI |
1S/C17H19N3/c1-3-12-19(15-8-10-18-11-9-15)20-13-14(2)16-6-4-5-7-17(16)20/h4-11,13H,3,12H2,1-2H3
|
||||
| InChIKey |
JFXXREWKFGYUCE-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Alpha-2C adrenergic receptor | Target Info | Inhibitor | [534087] | |
| Alpha-2A adrenergic receptor | Target Info | Inhibitor | [534087] | ||
| Alpha-2B adrenergic receptor | Target Info | Inhibitor | [534087] | ||
| PANTHER Pathway | Alpha adrenergic receptor signaling pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathwayP00002:Alpha adrenergic receptor signaling pathwayP00002:Alpha adrenergic receptor signaling pathway | |||||
| Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| References | |||||